NASDAQ · Drug Manufacturers - Specialty & Generic

Avadel Pharmaceuticals plc (AVDL) Stock

$21.64 +0.00% NASDAQ: AVDL Healthcare

Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials.

Valuation

MetricValue
Price$21.64
Market Cap$2.12B
P/E Ratio431.08
P/B Ratio21.39
P/S Ratio10.72
EPS (TTM)$0.05
52-Week High$23.57
52-Week Low$6.38
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE5.44%
ROA2.39%
ROCE5.71%
Gross Margin95.49%
Operating Margin3.95%
Net Margin2.41%
Debt/Equity0.38
Current Ratio2.76

Annual Financials (USD)

Metric20202021202220232024
Revenue$22.0M$0$0$28.0M$169.0M
Operating Profit$6.0M$-86.0M$-99.0M$-138.0M$-42.0M
Net Profit$7.0M$-77.0M$-137.0M$-160.0M$-49.0M
EPS$0.13$-1.32$-2.29$-2.00$-0.51
Op Margin26.0%——-493.0%-25.1%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$312.0M$247.0M$133.0M$165.0M$164.0M
Total Liabilities$149.0M$169.0M$154.0M$77.0M$90.0M
Cash$72.0M$51.0M$74.0M$31.0M$51.0M
Borrowings$131.0M$145.0M$131.0M$3.0M$2.0M

Latest News

Veradermics stock jumps again on female hair loss drug win Clinical Trials Arena · Jul 16, 2026 Ireland seeks views on draft textile EPR scheme Just Style · Jul 16, 2026 Pregis reports 55% revenue in 2025 from sustainable products Packaging Gateway · Jul 16, 2026 PureCycle alliance targets 2027 launch for recycled BOPP films in Japan Packaging Gateway · Jul 16, 2026 UK launches hi-tech mission to study Greenland ice melt AFP · Jul 16, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-49.0M$-77.0M$-70.0M$-129.0M$-47.0M
Investing Cash Flow$-70.0M$57.0M$79.0M$-50.0M$52.0M
Financing Cash Flow$0$0$-11.0M$28.0M$7.0M
Net Cash Flow$62.0M$-21.0M$23.0M$-43.0M$20.0M
Free Cash Flow$-49.0M$-77.0M$-71.0M$-129.0M$-47.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.66
EV / EBITDA177.56
FCF Yield1.30%
Quick Ratio2.37
Interest Coverage1.12
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALVOAlvotech $3.16 +3.10% -10.76 $1.07B 0.00%
ANIP $82.63 +3.44% 24.92 $1.88B 0.00%
BGMBGM Group Ltd. $0.30 -1.10% -1.82 $59.61M 0.00%
EVOEvotec SE $2.01 -6.07% -3.26 $713.93M 0.00%
GRDN $43.83 +11.05% 45.92 $2.78B 0.00%

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.

Avadel Pharmaceuticals plc is headquartered in IE.

Avadel Pharmaceuticals plc (AVDL) stock trades at $21.64 with a market capitalization of $2.12B. The stock is valued at a price-to-earnings (P/E) ratio of 431.08, price-to-book of 21.39, price-to-sales of 10.72. Over the past 52 weeks the stock has ranged between $6.38 and $23.57, and currently trades 8.2% below its 52-week high.

On profitability, Avadel Pharmaceuticals plc generates a return on equity (ROE) of 5.44%, return on capital employed of 5.71%, an operating margin of 3.95%, a net profit margin of 2.41%.

Official website: www.avadel.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides